AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05071885 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: games based exercise
Description: Range of motion and strengthening exercises
Study NCT04038515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0 mg/mL
Description: E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
Study NCT04038515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 6 mg/mL
Description: E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
Study NCT04038515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 12 mg/mL
Description: E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
Study NCT05658380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine
Description: patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
Study NCT05658380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
Study NCT05550441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The experimental group received dapagliflozin (10 mg qd) for 1 year.
Study NCT05550441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo group received placebo for 1 year.
Study NCT04364620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-16B5
Description: AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).
Study NCT04364620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer
Study NCT04958746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: intravenous bolus
Study NCT04958746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: intravenous bolus
Study NCT05228561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application Supported Nutrition and Diabetes Education
Description: With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
Study NCT06103994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multistrain probiotic
Description: Multistrain Probiotic
Study NCT04843696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)
Description: breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
Study NCT04843696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)
Description: breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
Study NCT06103994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05338879 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: No study treatment will be administered on this study.
Study NCT05432479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks
Study NCT05432479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05284916 — intervention group
Intervention type: BEHAVIORAL
Intervention: liver diseases admissions
Description: The different patterns of liver disease related admissions after the era of DAAS
Study NCT05150210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Surgery
Description: da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
Study NCT05116696 — intervention group
Intervention type: PROCEDURE
Intervention: For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery
Description: For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy
Study NCT04740697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
Description: Each included patient will be referred to the health care staff for a blood sample:~* for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~* for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...).
Study NCT04038515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 24 mg/mL
Description: E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
Study NCT05591716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral same-session flexible ureterorenoscopy
Description: The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
Study NCT05591716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral same-session flexible ureterorenoscopy
Description: The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
Study NCT06464419 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: Measurement of optic nerve sheath diameter by ultrasound
Study NCT05350189 — intervention group
Intervention type: DRUG
Intervention: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Description: At discretion of attending physician
Study NCT06502834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D piger
Description: Probiotic d piger
Study NCT06502834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05556538 — intervention group
Intervention type: PROCEDURE
Intervention: Transforaminal Epidural Steroid Injection
Description: Patients are placed in the prone position, with a pillow under their abdomen (to reduce lumbar lordosis) and taken to the operating table. The procedure area is cleaned 3 times with povidone-iodine antiseptic and covered with a sterile cover. In order to view the foramen to be processed, the fluoroscopy arm is evaluated at AP-oblique / cranial or caudal angles to obtain an optimal image. Local anesthetic (3 cc 2% prilocaine) is injected into the skin and subcutaneous tissue. The spinal Quincke 21-gauge 90 mm needle is advanced by targeting the relevant foramen under the guidance of fluoroscopy image. Needle position is confirmed by taking a lateral view. Needle aspiration is checked for blood. 1-2 ml of contrast material is injected to confirm that there is no vascular distribution and that it is in the epidural space. When distribution without vascular invasion is observed, an injection of a mixture of 10 mg dexamethasone, 1 cc saline and 1 cc (0.5%) bupivacaine is performed.
Study NCT04038515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Menthol' flavor
Description: E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
Study NCT05660447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
Description: One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
Study NCT05660447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Description: Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
Study NCT06037408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mM sodium pyruvate nasal spray
Description: The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
Study NCT06037408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo control nasal spray
Description: The placebo is 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
Study NCT06124456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Control Group
Description: Subjects in the usual care control group will receive health education as the attention control. The program will consist of eight 150-minute bi-weekly sessions covering major health issues relating to general health and NAFLD, to be obtained from publicly accessible resources from the Hong Kong Department of Health. Health education information on non-communicable diseases (e.g., cancers, diabetes, coronary heart diseases, obesity, and mental illness), infectious diseases (e.g., COVID-19), and a healthy lifestyle (e.g., balanced diet, physical activity, good sleep, tobacco use, alcohol cessation, and stress management) will also be distributed to the subjects in the exercise groups through recorded presentation videos and leaflets/pamphlets during the first 16 weeks.
Study NCT06100406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofield tuning
Description: Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected.
Study NCT06510972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strategy for continuing oral intake
Description: Patients will be able to ingest liquids or solid food orally, at any frequency and in any quantity they wish, according to their tolerance, with paramedical assistance if necessary.
Study NCT06510972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fasting strategy
Description: The patient will not be able to ingest liquids or solid food.
Study NCT06124456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity Exercise Intervention
Description: The walking time in each session will be 50 minutes for the moderate-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
Study NCT06124456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity Exercise Intervention
Description: The walking time in each session will be 25 minutes for the vigorous-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
Study NCT04038515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Menthol/Mint' flavor
Description: E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
Study NCT04038515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Green Apple' flavor
Description: E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
Study NCT04038515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Watermelon' flavor
Description: E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
Study NCT04038515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Unflavored'
Description: E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
Study NCT05492175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: robotic practice
Description: According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
Study NCT03718858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene Block
Description: 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
Study NCT03718858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Trunk Nerve Block
Description: 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.
Study NCT05492175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic practice
Description: According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
Study NCT05492175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinetic exergaming
Description: All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
Study NCT05492175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinetic exergaming
Description: All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
Study NCT05492175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Participants in control group will receive 30 minutes of therapist-mediated conventional therapy per session. The training protocols of the conventional therapy will use occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their personal needs. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The content of the functional tasks will be decided together by participants and therapists, such as picking up and putting down items in a box, lifting two soft drink bottles, and so on.
Study NCT04927572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX114
Description: Active Comparator
Study NCT04927572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo Comparator
Study NCT05490966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric trunk extensor muscles fatigue
Description: Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
Study NCT05082727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KOVIR (TD0068) oral softgel
Description: KOVIR (TD0068) is a softgel containing Allium sativum extract 270mg, Colostrum156.4 mg, fine powder mixed herbs 43.6mg
Study NCT05082727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral softgel
Description: Placebo
Study NCT05632926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg CBL-514
Description: CBL-514 will be administered at the raised area of cellulite.
Study NCT05632926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg CBL-514
Description: CBL-514 will be administered at the raised area of cellulite.
Study NCT05632926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg CBL-514
Description: CBL-514 will be administered at the raised area of cellulite.
Study NCT06264297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.
Study NCT06264297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.